Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BofA Securities Starts C4 Therapeutics at Buy With $54 Price Target

11/23/2021 | 08:12am EST


ę MT Newswires 2021
All news about C4 THERAPEUTICS, INC.
01/21C4 THERAPEUTICS : Financial Statements - Form 8-K/A
PU
01/21C4 THERAPEUTICS, INC. Financial Statements and Exhibits (form 8-K/A)
AQ
01/10C4 Therapeutics Says Liquidity Position Sufficient Through 2024; Shares Climb
MT
01/10C4 THERAPEUTICS : Announces 2022 Key Milestones to Advance Targeted Protein Degradation Po..
PU
01/10C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
AQ
01/10C4 THERAPEUTICS : Corporate Presentation – January 2022
PU
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
GL
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
CI
01/03C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021C4 THERAPEUTICS : CFT7455 ASH Trial-in-Progress Poster Presentation
PU
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 33,0 M - -
Net income 2021 -96,9 M - -
Net cash 2021 378 M - -
P/E ratio 2021 -11,1x
Yield 2021 -
Capitalization 1 138 M 1 138 M -
EV / Sales 2021 23,0x
EV / Sales 2022 27,8x
Nbr of Employees 99
Free-Float -
Chart C4 THERAPEUTICS, INC.
Duration : Period :
C4 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends C4 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 23,40 $
Average target price 60,67 $
Spread / Average Target 159%
EPS Revisions
Managers and Directors
Andrew J. Hirsch President, Chief Executive Officer & Director
Lauren White Treasurer, Chief Financial & Accounting Officer
Marc A. Cohen Executive Chairman
Adam S. Crystal Chief Medical Officer
Stewart Fisher Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
C4 THERAPEUTICS, INC.-27.33%1 138
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508